Trial Profile
Immunogenicity and Safety of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine Given in Japanese Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2014
Price :
$35
*
At a glance
- Drugs Typhoid vaccine Vi-polysaccharide (Primary)
- Indications Typhoid
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2012 New trial record